---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-21-000045"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2021-09-17T23:59:59+00:00"
generated_at: "2026-06-29T02:55:22.233579+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Travere Therapeutics appoints Sandra Calvin as Chief Accounting Officer effective Sept 15, 2021

## Summary
- Sandra Calvin, 56, appointed Vice President, Corporate Controller and Chief Accounting Officer.
- Calvin has served as VP, Corporate Controller since April 2018; joined the company in 2014.
- Laura Clague remains CFO and principal financial officer; Calvin assumes principal accounting officer duties.
- Calvin is a CPA (inactive) with prior roles at Amylin Pharmaceuticals and Vical Incorporated.

## SEC filing metadata
- accession: 0001438533-21-000045
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2021-09-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853321000045/0001438533-21-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853321000045/tvtx-20210914.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-21-000045
- JSON: https://secwatch.observer/filing/0001438533-21-000045.json
- Plain text: https://secwatch.observer/filing/0001438533-21-000045.txt

## Key facts
- Executive change
  Sandra Calvin was appointed as Vice President, Corporate Controller and Chief Accounting Officer at Travere Therapeutics, Inc..
  - Action: appointed
  - Role: Vice President, Corporate Controller and Chief Accounting Officer
  source text: On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved the appointment of Sandra Calvin as the Company’s principal accounting officer, effective September 15, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853321000045/0001438533-21-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.